Literature DB >> 9664784

Psychopharmacologic treatment of depression in the medically ill.

K Beliles1, A Stoudemire.   

Abstract

Appropriate selection of an antidepressant agent in medically ill patients requires a careful risk-benefit assessment matching the pharmacokinetic and pharmacodynamic properties of the drug being considered against the patient's physiological vulnerabilities, potential for drug interactions, and primary symptoms of the patient's depression. While in the past antidepressant drug selection was limited by the almost sole availability of the tricyclic antidepressants, newer drugs such as selective serotonin reuptake inhibitors, bupropion, and venlafaxine have vastly simplified treating depression in the medically ill. In refractory cases of depression in patients with medical illness, electroconvulsive therapy can be used with appropriate anesthetic management.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664784     DOI: 10.1016/S0033-3182(98)71339-8

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  13 in total

1.  Emotional dimensions of chronic disease.

Authors:  J Turner; B Kelly
Journal:  West J Med       Date:  2000-02

2.  Identifying and managing depression in the medical patient.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  Heart and mind: (2) psychotropic and cardiovascular therapeutics.

Authors:  S U Shah; Z Iqbal; A White; S White
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

4.  Depressive symptom patterns and their consequences for diagnosis of affective disorders in cancer patients.

Authors:  Katrin Reuter; Simone Raugust; Jürgen Bengel; Martin Härter
Journal:  Support Care Cancer       Date:  2004-10-09       Impact factor: 3.603

Review 5.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  [Electroconvulsive therapy at the Department of Psychiatry and Psychotherapy, University of Munich. Development during the years 1995-2002].

Authors:  T C Baghai; A Marcuse; H-J Möller; R Rupprecht
Journal:  Nervenarzt       Date:  2005-05       Impact factor: 1.214

7.  Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis.

Authors:  Gursharanjit Singh; Bijaya Ghosh; Dave Kaushalkumar; Vanita Somsekhar
Journal:  AAPS PharmSciTech       Date:  2008-07-01       Impact factor: 3.246

Review 8.  Management of psychiatric comorbidity in fibromyalgia.

Authors:  Lesley M Arnold
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

9.  Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment.

Authors:  Enrico Bellato; Eleonora Marini; Filippo Castoldi; Nicola Barbasetti; Lorenzo Mattei; Davide Edoardo Bonasia; Davide Blonna
Journal:  Pain Res Treat       Date:  2012-11-04

Review 10.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.